共 49 条
- [41] Low incidence rate of respiratory and viral infections over 5 years of treatment with tildrakizumab in patients with moderate-to-severe psoriasis: pooled analysis from reSURFACE 1 and reSURFACE 2 phase 3 trialsJOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2021, 35 (11) : E709 - E711Thaci, D.Jullien, D.Egeberg, A.Carrascosa, J. M.Wu, J. J.Pau-Charles, I.Gisondi, P.
- [42] Comparable and consistent efficacy responses with up to 3 years of guselkumab treatment in patients with moderate-to-severe plaque psoriasis regardless of prior treatment: Pooled analysis from the VOYAGE 1 and VOYAGE 2 trialsJOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2019, 81 (04) : AB185 - AB185Gordon, K.Guenther, L.Pinter, A.Choe, Y. -B.Song, M.Li, S.Fakharzadeh, S.Shen, Y-K.Tsai, T-F.
- [43] Efficacy of anifrolumab across organ domains in patients with moderate-to-severe systemic lupus erythematosus: a post-hoc analysis of pooled data from the TULIP-1 and TULIP-2 trialsLANCET RHEUMATOLOGY, 2022, 4 (04): : E282 - E292Morand, Eric F.Furie, Richard A.Bruce, Ian N.Vital, Edward M.Dall'Era, MariaMaho, EmmanuellePineda, LiliaTummala, Raj
- [44] Indacaterol/glycopyrrolate Improves Health Related Quality Of Life In Us Patients With COPD: A Subgroup Analysis From The Pooled Flight1 And Flight2 StudiesAMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2016, 193Mahler, D. A.Ayers, T.Patalano, F.Maitra, S.Banerji, D.
- [45] Improvement In Lung Function With Indacaterol/glycopyrrolate (ind/gly) In Patients With Moderate To Severe COPD From The Us: A Subgroup Analysis From The Flight1 And Flight2 StudiesAMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2016, 193Kerwin, E.Mahler, D. A.FowlerTaylor, A.Maitra, S.Banerji, D.
- [46] Dupilumab improves patient-reported symptoms of atopic dermatitis, symptoms of anxiety and depression, and health-related quality of life in moderate-to-severe atopic dermatitis: analysis of pooled data from the randomized trials SOLO 1 and SOLO 2JOURNAL OF DERMATOLOGICAL TREATMENT, 2020, 31 (06) : 606 - 614Cork, Michael J.Eckert, LaurentSimpson, Eric L.Armstrong, AprilBarbarot, SebastienPuig, LuisGirolomoni, Giampierode Bruin-Weller, MarjoleinWollenberg, AndreasKataoka, YokoRemitz, AnitaBeissert, StefanMastey, VeraArdeleanu, MariusChen, ZhenGadkari, AbhijitChao, Jingdong
- [47] Upadacitinib with or without topical corticosteroids improves health-related quality of life in adolescent and adult patients with moderate-to-severe atopic dermatitis: results from three phase III studies (Measure Up 1, Measure Up 2 and AD Up)BRITISH JOURNAL OF DERMATOLOGY, 2022, 187 (03) : E81 - E81Prajapati, Vimal H.Rosmarin, DavidShumack, StephenCalimlim, Brian M.Takemoto, ShunyaHu, XiaofeiLadizinski, BarryWarren, Richard B.
- [48] Mediation analysis of independent treatment effect of guselkumab on health-related quality of life in patients with moderate to severe plaque-type psoriasis: Results from 2 phase 3 studies VOYAGE-1&2JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2021, 85 (03) : AB128 - AB128Armstrong, April W.Liu, YanLi, NanReich, KristianFoley, PeterLi, ShuFakharzadeh, StevenPapp, Kim A.Han, Chenglong
- [49] Lebrikizumab is associated with improvements in patient-reported symptoms and quality-of-life measures across Eczema Area and Severity Index response categories: pooled results from phase-3 randomized ADvocate1 and ADvocate2 studies in patients with moderate-to-severe atopic dermatitisJOURNAL OF DERMATOLOGICAL TREATMENT, 2025, 36 (01)Blauvelt, AndrewKircik, LeonSchlesinger, ToddPierce, EvangelineBurge, RusselBehling, MichaelAtwater, Amber ReckElmaraghy, HanyArmstrong, April